
Tyme Technologies TYME
Tyme Technologies EV - Enterprise Value | TYME
Annual EV - Enterprise Value Tyme Technologies
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.81 M | -57.6 M | 213 M | 115 M | 226 M | 270 M | 249 M | 757 M | 2.63 M | -50 K | -14 K | -6.9 K |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 757 M | -57.6 M | 147 M |
EV - Enterprise Value of other stocks in the Biotechnology industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Foghorn Therapeutics
FHTX
|
582 M | $ 1.86 | -2.62 % | $ 117 M | ||
|
Ocugen
OCGN
|
652 M | $ 0.93 | 13.53 % | $ 291 M | ||
|
Oncolytics Biotech
ONCY
|
32.6 M | $ 0.44 | -2.01 % | $ 42.2 M | ||
|
Minerva Neurosciences
NERV
|
213 M | $ 2.42 | 5.0 % | $ 20.5 M | ||
|
Kamada Ltd.
KMDA
|
415 M | $ 7.22 | 5.09 % | $ 416 M | ||
|
Neurocrine Biosciences
NBIX
|
665 M | $ 164.42 | 2.91 % | $ 16.4 B | ||
|
Nanobiotix S.A.
NBTX
|
1.45 T | $ 30.7 | 2.05 % | $ 1.47 T | ||
|
Mereo BioPharma Group plc
MREO
|
2.03 B | $ 0.28 | 0.93 % | $ 223 M | ||
|
Maravai LifeSciences Holdings
MRVI
|
488 M | $ 7.53 | 7.81 % | $ 1.09 B | ||
|
Lexicon Pharmaceuticals
LXRX
|
635 M | $ 1.78 | 10.25 % | $ 646 M | ||
|
Moleculin Biotech
MBRX
|
706 K | $ 8.87 | 1.6 % | $ 10.5 M | ||
|
Nurix Therapeutics
NRIX
|
1.47 B | $ 15.3 | 3.1 % | $ 1.33 B | ||
|
Nkarta
NKTX
|
210 M | $ 1.75 | 11.15 % | $ 129 M | ||
|
MacroGenics
MGNX
|
293 M | $ 2.35 | 5.86 % | $ 148 M | ||
|
Protagonist Therapeutics
PTGX
|
5.46 B | $ 131.96 | -2.54 % | $ 8.39 B | ||
|
Nuvation Bio
NUVB
|
2.12 B | $ 4.15 | -0.72 % | $ 1.42 B | ||
|
Novo Nordisk A/S
NVO
|
541 B | $ 40.36 | 0.21 % | $ 179 B | ||
|
Marker Therapeutics
MRKR
|
6.72 M | $ 0.91 | 0.95 % | $ 13.9 M | ||
|
NextCure
NXTC
|
25.3 M | $ 5.55 | 8.61 % | $ 15.8 M | ||
|
PMV Pharmaceuticals
PMVP
|
59.5 M | $ 1.25 | -1.57 % | $ 65.7 M | ||
|
Olema Pharmaceuticals
OLMA
|
1.45 B | $ 7.32 | 8.21 % | $ 637 M | ||
|
Kymera Therapeutics
KYMR
|
7.74 B | $ 132.5 | 3.42 % | $ 11.2 B | ||
|
Oragenics
OGEN
|
-888 K | $ 0.35 | 0.29 % | $ 755 K | ||
|
Ovid Therapeutics
OVID
|
307 M | $ 2.86 | 10.66 % | $ 372 M | ||
|
Passage Bio
PASG
|
10.1 M | $ 3.9 | 12.72 % | $ 12.5 M | ||
|
Vaxcyte
PCVX
|
8.52 B | $ 63.86 | 3.13 % | $ 8.69 B | ||
|
Relay Therapeutics
RLAY
|
516 M | $ 18.59 | 9.32 % | $ 3.19 B | ||
|
Precigen
PGEN
|
1.07 B | $ 4.47 | 5.81 % | $ 1.4 B | ||
|
Avidity Biosciences
RNA
|
9.93 B | $ 8.36 | 0.48 % | $ 1.15 B | ||
|
Phio Pharmaceuticals Corp.
PHIO
|
-12.6 M | $ 0.8 | -1.38 % | $ 4.79 M | ||
|
Praxis Precision Medicines
PRAX
|
7.01 B | $ 277.94 | 5.85 % | $ 6.25 B | ||
|
Prelude Therapeutics Incorporated
PRLD
|
314 M | $ 3.59 | 0.98 % | $ 276 M | ||
|
ProQR Therapeutics N.V.
PRQR
|
133 M | $ 1.36 | 1.88 % | $ 143 M | ||
|
Ocular Therapeutix
OCUL
|
1.12 B | $ 6.61 | 2.8 % | $ 1.24 B | ||
|
PolyPid Ltd.
PYPD
|
61.3 M | $ 6.08 | 7.23 % | $ 99.4 M | ||
|
Outlook Therapeutics
OTLK
|
104 M | $ 0.44 | -0.93 % | $ 15.3 M | ||
|
uniQure N.V.
QURE
|
1.17 B | $ 21.68 | 3.19 % | $ 1.25 B | ||
|
Ultragenyx Pharmaceutical
RARE
|
3.2 B | $ 15.48 | -0.58 % | $ 1.53 B | ||
|
Rafael Holdings
RFL
|
48.1 M | $ 1.02 | -4.67 % | $ 52.4 M | ||
|
REGENXBIO
RGNX
|
759 M | $ 7.62 | 3.25 % | $ 393 M | ||
|
Rigel Pharmaceuticals
RIGL
|
679 M | $ 39.52 | -13.54 % | $ 711 M | ||
|
Celsion Corporation
CLSN
|
-3.55 M | - | -6.63 % | $ 13.9 M | ||
|
I-Mab
IMAB
|
127 M | - | - | $ 866 M | ||
|
Tenax Therapeutics
TENX
|
479 M | $ 1.68 | 3.07 % | $ 65.9 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
167 B | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
174 M | - | -13.47 % | $ 169 M | ||
|
Scholar Rock Holding Corporation
SRRK
|
4.92 B | $ 46.77 | 2.78 % | $ 5.36 B | ||
|
CureVac N.V.
CVAC
|
-376 M | - | - | $ 867 M |